A.P.L.
Clinical safety rating
cautionAcetaminophen (APAP) is a widely used analgesic and antipyretic, commonly employed for pain and fever management, including during pregnancy. It is considered the first-line treatment for mild to moderate pain and fever in pregnant women due to its favorable safety profile.
Acetaminophen (APAP) is a widely used analgesic and antipyretic, commonly employed for pain and fever management, including during pregnancy. It is considered the first-line treatment for mild to moderate pain and fever in pregnant women due to its favorable safety profile.
Induction of ovulation in anovulatory infertile womenTreatment of hypogonadism and cryptorchidism in malesOff-label: Assisted reproductive technology (ART) protocols
nauseavomitingheadacherashpruritussweatingconstipation
A.P.L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
| Metabolism | Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione. |
| Excretion | Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined). |
| Half-life | Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect. |
| Protein binding | 80–90% bound to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | 0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver). |
| Bioavailability | IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used). |
| Onset of Action | Intramuscular: 30–60 minutes; Subcutaneous: 45–90 minutes; Intravenous: 15–30 minutes. |
| Duration of Action | 4–6 hours (IM/SC) dependent on dose and gonadal response; shorter with IV. |
| Molecular Weight | 36700 |
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
| Dosage form | INJECTABLE |
| Renal impairment | No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (CrCl < 10 mL/min), extend dosing interval to every 8 hours. |
| Liver impairment | Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease. |
| Pediatric use | Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day. |
| Geriatric use | No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day. |
| 1st trimester | A.P.L. is human chorionic gonadotropin (hCG). There are no adequate studies in pregnant women; use only if potential benefit justifies risk. May cause fetal harm if used during pregnancy. |
| 2nd trimester | Similar to first trimester; avoid use unless clearly needed. hCG can stimulate progesterone production, potentially affecting pregnancy. |
| 3rd trimester | Use is generally contraindicated as hCG may interfere with normal pregnancy physiology. |
Clinical note
Acetaminophen is generally considered safe for use during pregnancy (Category B). It is the analgesic and antipyretic of choice for mild to moderate pain and fever in pregnant women at recommended doses. Chronic high dose use may be associated with adverse outcomes, but standard therapeutic use is not linked to increased risk of malformations.
| Placental transfer | hCG crosses the placenta; it is a normal placental hormone. Exogenous hCG administration can increase maternal and fetal levels. |
| Breastfeeding | hCG is not known to be excreted in human milk. However, caution is advised due to potential hormonal effects on the infant. Consider benefits of breastfeeding and risk of infant exposure. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction). |
| Fetal Monitoring | Monitor for signs of ovarian hyperstimulation syndrome (OHSS) including pelvic pain, distension, rapid weight gain, and oliguria. Ultrasound monitoring of ovarian size and follicle development. In pregnancy, monitor for multiple gestation and potential pregnancy complications. |
| Fertility Effects | Chorionic gonadotropin is used to trigger ovulation and support luteal phase. May increase likelihood of multiple gestation. No known permanent adverse effects on fertility. However, repeated use in ovulation induction protocols may contribute to OHSS. |
■ FDA Black Box Warning
No black box warning.
| Common Effects | nausea, vomiting, headache, rash, pruritus, sweating, constipation |
| Serious Effects | Acute liver failure (often due to overdose), severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). |
Hypersensitivity to hCG or any componentPrecocious pubertyProstatic carcinoma or other androgen-dependent neoplasmsPregnancy (therapeutic use during pregnancy is contraindicated)
| Precautions | May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females, Increased risk of thromboembolic events, Precocious puberty in males, Not for use in prepubertal children unless for cryptorchidism |
| Food/Dietary | No known food interactions. Avoid alcohol during treatment. |
| Clinical Pearls | A.P.L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism. |
| Patient Advice | This medication is given as an injection exactly as prescribed to trigger ovulation. · A single dose is usually sufficient; follow your doctor's timing instructions closely. · Common side effects include headache, fatigue, and injection site reactions. · Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS). · Report symptoms of blood clots: leg pain, chest pain, or shortness of breath. |
Loading safety data…